Thirty-seven persons were identified with GB virus C (GBV-C
nors, assess the impact of a chronic carriership on the liver histology, and determine whether GBV-C replicates in hepatocytes.
Materials and Methods
Blood donors. Since the prevalence of GBV-C in healthy Swedish subjects is about 3% [8] , we decided to screen 1000 blood donors to identify 30 GBV-C RNA-positive donors for further examination. In total, 1254 volunteer consecutive blood donors attending the Blood Transfusion Service Centre at the South Hospital, Stockholm, were screened for GBV-C RNA in the spring of 1998. Donors seronegative for human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) markers by commercial screening assays (Abbott Laboratories, Abbott Park, IL) and subsequently found to be positive for GBV-C RNA were invited to attend a clinical evaluation by a hepatologist at the Division of Infectious Diseases, Huddinge University Hospital. At the initial consultation, a serum sample was drawn for a repeat GBV-C RNA analysis, and a history of risk behavior was sought. Routine liver function tests were performed, including serum alanine aminotransferase (ALT), serum bilirubin, serum albumin, and prothrombin time. GBV-C RNA-positive persons were offered further evaluation, including a liver biopsy to assess whether liver injury had been induced by the GBV-C infection.
Liver biopsies and histology. Liver biopsies of 17 subjects were done by a slightly modified Menghini technique. The biopsy specimens were fixed in Histofix and were embedded in paraffin. Sections (4 mm) were stained with hematoxylin-eosin, van Gieson, periodic acid-Schiff with and without previous diastase digestions, Perl's iron, and a reticulin stain.
Detection of GBV-C in serum and liver biopsies. Serum GBV-C RNA was detected by a nested reverse transcription polymerase chain reaction (PCR) based on primers from the conserved 5 untranslated region (UTR) of the GBV-C genome, as described elsewhere in detail [7] . Expression of GBV-C 5 -UTR transcripts in liver biopsies were detected by in situ hybridization (ISH). To pro-duce labeled RNA probes, amplified 5 -UTR fragments were cloned by commercial kit (TA Cloning; Invitrogen, San Diego). The orientation of the inserted fragment was confirmed by PCR using M13 reverse primers, together with either HGV 3 (sense) or HGV 4 (antisense) primers [7] . The plasmid DNA was then linearized by cleavage, using BamHI (Boehringer Mannheim, Mannheim, Germany), and was purified by phenol-chloroform-ethanol precipitation, according to standard protocols. Transcription and digoxygenin labeling of RNA probes was done by commercial kit (DIG RNA labeling kit; Boehringer Mannheim). The labeled antisense and sense RNA probes were used to detect positive and negative strands of GBV-C/HGV RNA, respectively.
ISH using the labeled GBV-C RNA probes was performed as described elsewhere [15] . In brief, paraffin-embedded liver biopsy (4 mm) sections were deparaffinized with xylene, hydrated using ethanol, and were immersed in 0.2 M HCl. The sections were subjected to proteolytic digestion with proteinase K (Sigma, St. Louis), rinsed with glycine, postfixed, acetylated, and then were prehybridized. Hybridization was done at 42ЊC with 250 ng of prewarmed labeled RNA probes in a humid box overnight. Nonbound RNA probes were removed by RNase. RNA-RNA hybrids were detected by an anti-digoxygenin alkaline phosphatase conjugate (Boehringer Mannheim), followed by nitroblue tetrazolium-5-bromo-4-chloro-indoyl phosphate substrate (Boehringer Mannheim). A successful ISH was visualized by light microscopy and showed an insoluble purple precipitate. As negative controls, we used liver biopsies from patients negative for GBV-C/HGV RNA in serum.
To further confirm the presence of GBV-C in liver tissue, we developed an in-house immunofluorescence (IF) assay to detect GBV-C/HGV E2 antigen. Paraffin-embedded liver tissue specimens were deparaffinized with xylene and were hydrated with ethanol. The sections then were treated with boiling citrate buffer for 15 min and were blocked with 10 mM NaPO 4 and 140 mM NaCl (pH 7.2; FA buffer) for 5 min. Mouse anti-GBV-C/HGV E2 diluted 1: 10 in FA buffer was added for 60 min in 37ЊC in a humidified box, and unbound antibodies were washed away with FA buffer for 5 min. Fluorescein isothiocyanate-marked anti-mouse IgG conjugate was then added diluted 1:15 in FA buffer and incubated for 30 min at 37ЊC. Rinsed sections were counterstained with Evan's blue for 3 min. After a final wash with reverse osmosis H 2 O, the sections were mounted. A successful IF was visualized by IF microscopy and showed green fluorescence. As controls, we used paraffin-embedded liver tissue specimens from persons negative for GBV-C/HGV RNA in serum.
Results

Clinical appearance of GBV-C infection in blood donors.
Of 1254 tested blood donors, 37 (3%) were positive for GBV-C RNA in serum by PCR. Thirty-three (89%) returned for a clinical examination (18 men and 15 women; mean age, 38 years [range, 23-53 years]). At follow-up 3-6 months later, 32 remained GBV-C RNA positive, and 1 had seroconverted and developed GBV-C E2 antibodies. Of the GBV-C RNA-positive persons, 17 (54%) agreed to undergo further evaluation, including a liver biopsy (table 1) .
Twenty-four (67%) of 33 donors (all heterosexual) reported their lifetime sex partners (mean, 33 partners; range, 4-100 partners). Of the 24 donors, 17 (71%) had у10 partners. Six (18%) of the 33 donors had received 1 blood transfusion or had experienced inoculation procedures (acupuncture, ; tattooing, n p 3 ; or local anesthesia in the Far East, ). Further posn p 1 n p 1 sible risk factors included medical occupation ( ), extensive n p 2 medical work-up including gastroscopy, traffic accident in Crete ( ), and work in the Middle East and Africa ( ). Aln p 1 n p 1 though 18% of the donors had a possible inoculation as a cause for transmission of their infection, all were negative for markers of blood-borne viral infections other than GBV-C.
Liver function tests, including ALT and aspartate aminotransferase (AST), serum bilirubin, serum albumin, serum IgG, and prothrombin time, were within normal limits in all 33 donors. The mean levels (ranges) for ALT, AST, serum (s) albumin, and sIgG for women were 0. Liver histology among GBV-C-infected blood donors. Liver biopsies were performed for 17 donors positive for GBV-C RNA in serum. At least 10 portal zones were analyzed in all subjects. In 11 (65%), the biopsies showed no histological changes. Of the remaining 6, 2 (12%) with a substantial overweight displayed marked steatosis, 3 (18%) had minimal fatty infiltration, and 1 had some iron deposition in the liver cells (table 1) . Thus, 65% of the biopsies were without histological changes, and 23% showed minimal changes. Two donors (T11551 and T6609; 12%) showed pathological steatosis. The 2 donors with fatty liver were overweight (body mass indices, 28.6 and 30.3, respectively). GBV-C carriage in the majority of our cases apparently was associated with normal histology. Minimal steatosis was not considered pathological.
Detection of GBV-C replication in liver biopsies from blood donors. The presence of GBV-C replication in the liver was determined by ISH and IF in biopsies of 15 GBV-C-infected donors and 7 hepatitis B surface antigen carriers without GBV-C viremia. Cells positive for GBV-C 5 -UTR strands were found in 7 (47%) of the 15 (table 1). In 3 of these 7, the replicative template (negative strand) was also detected (table 1). None of the 7 controls with chronic HBV infection displayed either positive-or negative-stranded GBV-C 5 -UTR sequences. In all 7 subjects with GBV-C replication determined by ISH, only a few cells (2-15 cells) per 10 portal zones were positive, indicating that only a minority of the liver cells had detectable levels of viral replication. The cells with GBV-C replication had a localization and morphology consistent with hepatocytes (figure 1) . In addition, viral replication was restricted mainly to the cytoplasmic compartment and was not detected in the nucleus (figure 1), consistent with a member of the flaviviridae family. The GBV-C E2 protein was detected in 7 (50%) of 14 analyzed liver sections from the GBV-C-infected donors but in Table 1 . Presence of GB virus C (GBV-C) in liver sections, as shown by the detection of 5 untranslated region (UTR)-positive and -negative strands by in situ hybridization (ISH) and the detection of the GBV-C envelope 2 (E2) protein by immunofluorescence (IF) in 15 donors with GBV-C viremia and 7 hepatitis B surface antigen carriers (controls) without GBV-C viremia. 
portal fibrosis with slender septa NOTE. Liver histological findings for GBV-C-positive donors are shown plus demographic data, ALT levels at biopsy, and no. of lifetime sex partners for GBV-C-positive donors. ALT, alanine aminotransferase (upper normal limit for males, 0.8 mkat/L; for females, 0.6 mkat/L); BMI, body mass index; ND, not done; ϩ, positive; Ϫ, negative. only 0 of 6 HBV-infected control biopsies. Four of the 7 biopsies with detectable GBV-C E2 protein were also positive by ISH (table 1 and figure 1) . Again, the localization and morphology of the GBV-C E2-expressing cells were consistent with hepatocytes. In all cases, the expression of the GBV-C E2 protein was restricted to the cytoplasmic compartment (figure 1).
Discussion
Because some major issues concerning infection with GBV-C have not been firmly established, it is unclear whether GBV-C causes viral hepatitis. Furthermore, it has been debated whether GBV-C replicates in the liver [12] [13] [14] . A major obstacle when evaluating the clinical importance of GBV-C is that most GBV-C-infected persons are within groups in which other hepatotropic virus infections are common [3] .
To clarify some of these issues, we studied solely GBV-C-infected healthy blood donors without serological markers for HBV, HCV, or HIV-1. In such persons, we found no clinical, biochemical, or histological signs of liver disease. This indicates that GBV-C does not harm the liver, at least not in viremic blood donors. However, we found firm evidence that GBV-C replicates in hepatocytes in these healthy donors. Both ISH and IF revealed cells that expressed GBV-C-encoded transcripts and proteins in the cytoplasm. This finding is consistent with the replication cycle and E2 protein expression of a member of the flaviviridae family. The localization and morphology of the GBV-C-expressing cells indicated that they were hepatocytes. Thus, GBV-C can infect and replicate in hepatocytes of the human liver, as shown elsewhere by ISH [12] . Whether the liver is the major site for GBV-C replication remains to be determined [13, 14] . The fact that few hepatocytes had detectable levels of GBV-C replication may explain earlier discrepancies concerning detection of GBV-C replication in the liver; however, this does not exclude the possibility that many more hepatocytes are infected, but with a viral gene and protein expression below the detection limits of our assays.
The 3% prevalence of GBV-C viremic blood donors in the absence of identified parenteral risk factors for the majority of blood donors suggests the possibility of other routes of infection, such as sexual transmission [10] . The high number of sex partners reported by many of our donors (71% had у10 partners; 26% had 130 lifetime partners), high figures for Swedes according to a national census (P. Tü ll, personal communication), indicates that sexual transmission might have been a significant factor. To conclude, we show that GBV-C/HGV replicates in hepatocytes but causes no injury to the liver in viremic blood donors. In concordance with this, no clinical or biochemical signs of liver disease were recorded in our donors, indicating that screening of blood donors for GBV-C due to fear of transmitting viral hepatitis may not be necessary.
